Key findings towards optimising adalimumab treatment: the concentration-effect curve.
about
Biologic efficacy optimization--a step towards personalized medicineAnti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort StudyComparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registryCost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockersClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.Second Korean guidelines for the management of ulcerative colitis.Management of Crohn's disease in poor responders to adalimumab.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al.Adalimumab concentration-based tapering strategy: as good as the recommended dosage.Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
P2860
Q26783657-33590DEB-C486-4B6A-8636-B60625639A0CQ28553954-6C63EE6D-2431-41E2-9801-F7E49E211423Q36472687-4F26F9E4-79B1-4811-8237-0160988193DFQ36776326-CCED1F91-0FC2-439A-A33D-C0451B372ACAQ36832755-EFA119F7-4A4A-49CA-B2E4-3C512CF763BBQ37118400-1A6E9B49-6712-433D-8E50-C086D6160CBCQ37562464-5C3931CD-1B8F-4F6D-A352-7D1FFEA39696Q37604498-672A0AEA-B4E0-499E-A298-DA626551EBA9Q37620900-B139A089-4534-4299-9968-64783D5A0F70Q37662503-F9CA1BBC-26E7-4042-9CF3-99A8FAE42C77Q37708656-DCFF01EF-A597-4BD4-98DB-7DC77FF5D489Q38462602-CE81CC9E-BF25-4B86-AA0D-D72C5FE15BE1Q38540353-B742F87B-E54A-4C42-9F6B-6F6877886B10Q38564877-E54D6267-DDBC-4ED9-83B9-9F03F1538B26Q38849974-D7520D5A-A2C4-47AF-BB96-731DC6E494FFQ38888137-AE975937-C449-4B02-84E1-3B57989AEA49Q38898145-8C6499FF-CC28-452C-BE16-869087551B5FQ39023180-FE4C0AD8-58F6-4F24-850F-C6A008139A90Q39042940-4579D8AC-4502-49C1-9395-CA450BE1DBC5Q39420995-087EA273-0F41-4B71-9EA6-88E360C02C40Q41819996-F064D64C-7987-4FE1-9DA0-DC328783ED66Q42373188-660C76D2-3A87-42EC-AAA5-EA58254460C6Q47380976-8E2F580F-E263-40C4-84AB-5474BF1FACBAQ47805665-A8540AE0-8348-4118-B8D2-E1CCB379B6ADQ47974635-5974A2FF-C797-4625-B1AC-DFE9A5776D2EQ48086481-D58CE039-7E9B-496B-82BC-D9168F885CF9Q48548520-4AE4B9C0-F7CE-45F1-91E2-1AFCB56B1DEFQ50014741-1AF2D5B8-019E-4DB7-BF14-51EA18FB1386Q51046105-5A256281-94D5-4527-9773-05AC42C962F3Q51627957-DDA5B4D7-3142-4F20-8303-AEA01B7E3AD7Q53364227-DA4900BA-2A71-4C92-8343-59F108D30645Q53366166-198CEBDE-0D01-4B91-8AA2-AD755C87CCD9
P2860
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@en
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@nl
type
label
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@en
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@nl
prefLabel
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@en
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@nl
P2093
P2860
P1476
Key findings towards optimising adalimumab treatment: the concentration-effect curve.
@en
P2093
Charlotte L Krieckaert
Desiree van der Kleij
Gertjan Wolbink
Lucien Aarden
Michael T Nurmohamed
Mieke F Pouw
Theo Rispens
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204172
P407
P577
2013-12-10T00:00:00Z